{"protocolSection": {"identificationModule": {"nctId": "NCT03045887", "orgStudyIdInfo": {"id": "202062"}, "secondaryIdInfos": [{"id": "2016-003188-21", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes", "officialTitle": "A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-02-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-08-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-02-03", "studyFirstSubmitQcDate": "2017-02-03", "studyFirstPostDateStruct": {"date": "2017-02-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-07-25", "resultsFirstSubmitQcDate": "2019-02-12", "resultsFirstPostDateStruct": {"date": "2019-05-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-10", "lastUpdatePostDateStruct": {"date": "2019-07-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study is the first administration of GSK2292767 to humans. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat inhaled doses of GSK2292767 in healthy smokers. This study is intended to provide sufficient confidence in the safety of the molecule and preliminary information on target engagement to allow progression to further repeat dose and proof of mechanism studies. This is a two part, single site, randomized, double-blind (sponsor open), placebo controlled study. Part A will consist of two 3-period interlocking cohorts to evaluate the safety, tolerability and pharmacokinetics of ascending single doses of GSK2292767 administered as a dry powder inhalation. Part B is planned to follow Part A and progression will be based on an acceptable safety, tolerability and pharmacokinetic profiles. Subjects will receive repeat doses of GSK2292767 once daily for 14 days during Part B."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["repeat dose", "GSK2292767", "smoke", "tolerability", "safety", "dry powder inhalation", "pharmacokinetics", "single dose"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 \u00b5g-GSK 1000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 \u00b5g in Period 2, and GSK2292767 1000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 1: GSK 50 \u00b5g-Placebo-GSK 1000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 50 \u00b5g in Period 1, placebo in Period 2, and GSK2292767 1000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 1: GSK 50 \u00b5g- GSK 200 \u00b5g-Placebo", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 50 \u00b5g in Period 1, GSK2292767 200 \u00b5g in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 1: GSK 50 \u00b5g-GSK 200 \u00b5g-GSK 1000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 50 \u00b5g in Period 1, GSK2292767 200 \u00b5g in Period 2, and GSK2292767 1000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg"]}, {"label": "Part A Cohort 2: Placebo-GSK 500 \u00b5g-GSK 2000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 \u00b5g in Period 2, and GSK2292767 2000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 500 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 2: GSK 100 \u00b5g-Placebo- GSK 2000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 100 \u00b5g in Period 1, placebo in Period 2, and GSK2292767 2000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-Placebo", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 100 \u00b5g in Period 1, GSK2292767 500 \u00b5g in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg", "Drug: Placebo"]}, {"label": "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-GSK 2000 \u00b5g", "type": "EXPERIMENTAL", "description": "Subjects will receive an inhaled single dose of GSK2292767 100 \u00b5g in Period 1, GSK2292767 500 \u00b5g in Period 2, GSK2292767 2000 \u00b5g in Period 3. There will be a washout of approximately 4 weeks between doses.", "interventionNames": ["Drug: GSK2292767 50 \u03bcg", "Drug: GSK2292767 500 \u03bcg"]}, {"label": "Part B: GSK", "type": "EXPERIMENTAL", "description": "Subjects will receive inhaled repeat dose of GSK2292767 2000 \u00b5g once daily for 14 days.", "interventionNames": ["Drug: GSK2292767 500 \u03bcg"]}, {"label": "Part B: Placebo", "type": "EXPERIMENTAL", "description": "Subjects will receive inhaled repeat dose of placebo once daily for 14 days.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "GSK2292767 50 \u03bcg", "description": "GSK2292767 50 \u03bcg blended with lactose and magnesium stearate per blister as powder for inhalation", "armGroupLabels": ["Part A Cohort 1: GSK 50 \u00b5g- GSK 200 \u00b5g-Placebo", "Part A Cohort 1: GSK 50 \u00b5g-GSK 200 \u00b5g-GSK 1000 \u00b5g", "Part A Cohort 1: GSK 50 \u00b5g-Placebo-GSK 1000 \u00b5g", "Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 \u00b5g-GSK 1000 \u00b5g", "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-GSK 2000 \u00b5g", "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-Placebo", "Part A Cohort 2: GSK 100 \u00b5g-Placebo- GSK 2000 \u00b5g"]}, {"type": "DRUG", "name": "GSK2292767 500 \u03bcg", "description": "GSK2292767 500 \u03bcg blended with lactose and magnesium stearate per blister as powder for inhalation", "armGroupLabels": ["Part A Cohort 1: GSK 50 \u00b5g-GSK 200 \u00b5g-GSK 1000 \u00b5g", "Part A Cohort 1: GSK 50 \u00b5g-Placebo-GSK 1000 \u00b5g", "Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 \u00b5g-GSK 1000 \u00b5g", "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-GSK 2000 \u00b5g", "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-Placebo", "Part A Cohort 2: GSK 100 \u00b5g-Placebo- GSK 2000 \u00b5g", "Part A Cohort 2: Placebo-GSK 500 \u00b5g-GSK 2000 \u00b5g", "Part B: GSK"]}, {"type": "DRUG", "name": "Placebo", "description": "Lactose as powder for inhalation", "armGroupLabels": ["Part A Cohort 1: GSK 50 \u00b5g- GSK 200 \u00b5g-Placebo", "Part A Cohort 1: GSK 50 \u00b5g-Placebo-GSK 1000 \u00b5g", "Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 \u00b5g-GSK 1000 \u00b5g", "Part A Cohort 2: GSK 100 \u00b5g-GSK 500 \u00b5g-Placebo", "Part A Cohort 2: GSK 100 \u00b5g-Placebo- GSK 2000 \u00b5g", "Part A Cohort 2: Placebo-GSK 500 \u00b5g-GSK 2000 \u00b5g", "Part B: Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Part A: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE)", "description": "An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants with 5 percent nSAEs and SAEs has been reported.", "timeFrame": "Up to 12 weeks"}, {"measure": "Part B: Number of Participants With Any AE and Any SAE", "description": "An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants with 5 percent nSAEs and SAEs has been reported.", "timeFrame": "Up to 4 weeks"}, {"measure": "Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)", "description": "Blood pressure in part A was assessed in a semi supine position with a completely automated device. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period"}, {"measure": "Part B: Change From Baseline in SBP and DBP", "description": "Blood pressure in part B were assessed in semi supine position with a completely automated device. SBP and DBP preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Change From Baseline in Heart Rate", "description": "Heart rate in part A was assessed in a semi supine position with a completely automated device. Heart rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period"}, {"measure": "Part B: Change From Baseline in Heart Rate", "description": "Heart rate in part B was assessed in a semi supine position with a completely automated device. Heart rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Change From Baseline in Respiratory Rate", "description": "Respiratory rate in part A was assessed in a semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period"}, {"measure": "Part B: Change From Baseline in Respiratory Rate", "description": "Respiratory rate in part B was assessed in a semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Change From Baseline in Tympanic Temperature", "description": "Tympanic temperature in part A was assessed in semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period"}, {"measure": "Part B: Change From Baseline in Tympanic Temperature", "description": "Tympanic temperature in part B was assessed in semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry at the indicated time. FEV1 measurements were repeated until three technically acceptable measurements (within 150 milliliter \\[mL\\] of each other) were made. Data for FEV1 for part A is presented here.", "timeFrame": "Day 1 (pre-dose and 1 hour)"}, {"measure": "Part B: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry at the indicated time. Existing spirometry equipment was used. FEV1 measurements were repeated until three technically acceptable measurements (within 150 mL of each other) were made. Data for FEV1 for part B is presented here.", "timeFrame": "Up to Day 14"}, {"measure": "Part A: Forced Vital Capacity (FVC)", "description": "FVC is a measure of lung function and is defined as total amount of air that can be exhaled during FEV1 test. FVC was planned to measured using spirometry. The FVC need to be normal at screening and is part of the Forced Expiratory ratio (FEV1/FVC) which should lie between 0.7-0.8 to indicate no chronic obstruction or restriction. The FVC was therefore only used at screening and requires no ongoing analysis during the study. All other indications of obstruction in the study, e.g. paradoxical bronchospasm was provided by the FEV1. The FVC therefore require no analysis.", "timeFrame": "Day 1 (pre-dose and 1 hour)"}, {"measure": "Part B: Forced Vital Capacity (FVC)", "description": "FVC is a measure of lung function and is defined as total amount of air that can be exhaled during FEV1 test. FVC was planned to measured using spirometry. The FVC need to be normal at screening and is part of the Forced Expiratory ratio (FEV1/FVC) which should lie between 0.7-0.8 to indicate no chronic obstruction or restriction. The FVC was therefore only used at screening and requires no ongoing analysis during the study. All other indications of obstruction in the study, e.g. paradoxical bronchospasm was provided by the FEV1. The FVC therefore require no analysis.", "timeFrame": "Day 1 (pre-dose and 1 hour)"}, {"measure": "Part A: Number of Participants With Electrocardiogram (ECG) Abnormalities", "description": "Triplicate/Single 12-lead ECG was obtained using an automated ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTFc intervals. Number of participants with abnormal clinically significant and abnormal-not clinically significant values at any time post-Baseline is presented.", "timeFrame": "Day 1 of each treatment period"}, {"measure": "Part B: Number of Participants With ECG Abnormalities", "description": "Triplicate/Single 12-lead ECG was obtained using an automated ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTFc intervals. Number of participants with abnormal clinically significant and abnormal-not clinically significant values at any time post-Baseline is presented.", "timeFrame": "Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Number of Participants With Clinical Chemistry Values of Potential Clinical Importance Criteria (PCC)", "description": "Number of participants with clinical chemistry values that changed from normal to high or low in part A are presented. Chemistry parameters for which PCC values were identified were: Alkaline Phosphatase, Alanine Amino Transferase, aspartate aminotransferase, Total Bilirubin, calcium, glucose, potassium and Sodium.", "timeFrame": "24 hours post-dose in each treatment period."}, {"measure": "Part B: Number of Participants With Clinical Chemistry Values of PCC", "description": "Number of participants with clinical chemistry values that changed from normal to high or low in part B are presented. Chemistry parameters for which PCC values were identified were: Alkaline Phosphatase, Alanine Amino Transferase, aspartate aminotransferase, Total Bilirubin, calcium, glucose, potassium and Sodium. Only participants with data available at specified time points were analyzed (represented by n=X in category titles)", "timeFrame": "Pre-dose on Days 2, 4, 6, 8, 10, 12, and 14, 24 hours post-dose on Day 14"}, {"measure": "Part A: Number of Participants With Hematology Values of PCC", "description": "Number of participants with hematology parameters of PCC which shifted from normal to high in part A are presented. Hematology parameters for which PCC values were identified were: Hemoglobin, Hematocrit, Lymphocytes, Total Neutrophils, Platelet count and White Blood Cell (WBC) Count. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles)", "timeFrame": "24 hours post-dose in each treatment period"}, {"measure": "Part B: Number of Participants With Hematology Values of PCC", "description": "Number of participants with hematology parameters of PCC which shifted from normal to high in part B are presented. Hematology parameters for which PCC values were identified were: Hemoglobin, Hematocrit, Lymphocytes, Total Neutrophils, Platelet count and WBC count", "timeFrame": "Pre-dose on Days 2, 4, 6, 8, 10, 12, and 14, 24 hours post-dose on Day 14"}], "secondaryOutcomes": [{"measure": "Part A: Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK2292767 for part A is presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). Pharmacokinetic population comprised of participants in the 'All participant' population for whom a pharmacokinetic sample was obtained and analyzed.", "timeFrame": "Pre-dose (5 minutes (min), 30 min, 45 min, 1 hour (hr), 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods"}, {"measure": "Part B: AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK2292767 for part B is presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14"}, {"measure": "Part A: Maximum Observed Plasma Drug Concentration (Cmax) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Five min post dose concentrations on Days 2-13 were assumed to be the Cmax values. Data for Cmax of GSK2292767 for part A is presented. Cmax is defined as maximum observed plasma concentration of GSK2292767.", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods"}, {"measure": "Part B: Cmax of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Five minute post dose concentrations on Days 2-13 were assumed to be the Cmax values. Data for Cmax of GSK2292767 for part B is presented.", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14"}, {"measure": "Part A: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Tmax of GSK2292767 for part A is presented.", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods"}, {"measure": "Part B: Tmax of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Tmax of GSK2292767 for part B is presented.", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14"}, {"measure": "Part A: Terminal Half-life (T1/2) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for T1/2 of GSK2292767 for part A is presented. T1/2 is defined as the time required for one half of the total amount of a particular substance in a biological system to be degraded by biological processes. Only those participants with data available at the specified time points were analyzed.", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods"}, {"measure": "Part B: T1/2 of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for T1/2 of GSK2292767 for part B is presented. T1/2 was defined as the time required for one half of the total amount of a particular substance in a biological system to be degraded by biological processes. Only those participants with data available at the specified time points were analyzed.", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14"}, {"measure": "Part A: Trough Concentrations (Ctau) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Ctau of GSK2292767 for part A is presented. Ctau is defined as the lowest concentration reached by a drug before the next dose is administered.", "timeFrame": "24 hr post dose in each of the 3 treatment periods"}, {"measure": "Part B: Ctau of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Ctau of GSK2292767 for part B is presented. Ctau is defined as the lowest concentration reached by a drug before the next dose is administered. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14"}, {"measure": "Part B: Concentration of GSK2292767 in Bronchoalveolar Lavage (BAL)", "description": "BAL samples were collected by bronchoscopy.", "timeFrame": "Day 15"}, {"measure": "Part B: Concentration of GSK2292767 in Lung Epithelial Lining Fluid (ELF)", "description": "ELF from the lung was extracted from BAL samples. ELF drug concentration was calculated as BAL fluid drug concentration multiplied by dilution factor where dilution factor = Plasma urea (pre-bronchoscopy) divided by BAL urea. NA indicates data not available. Only participants with data available at specified time points were analyzed (represented by n=X in category titles).", "timeFrame": "Day 15"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be 18 to 50 years of age inclusive, at the time of signing the informed consent\n* Participants who are overtly healthy as determined by medical evaluation including (medical history, physical examination, laboratory tests, and cardiac monitoring). A participant with a clinical abnormality or laboratory parameters outside the reference range expected for them and the population being studied may be included only if the Investigator believes that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or outcomes\n* Participants who are current daily cigarette smokers (manufactured and self-rolled). Must have smoked regularly in the 12-month period preceding the screening visit\n* Normal spirometry (FEV1 \\>=80% of predicted) at screening\n* Body weight \\>=50 kilograms (kg) and body mass index (BMI) within the range 18 to 31 kg/square meter (m\\^2) (inclusive)\n* Male and female\n\n  * Male participants: A male participant must agree to use contraception as detailed in the protocol during the treatment period and for at least from the time of first dose of study medication until at least 55 (5x11) hours plus an additional 90 days after the last dose of study medication and refrain from donating sperm during this period. GSK2292767 has a predicted half-life of approximately 11 hours\n  * Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP)\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol\n\nExclusion Criteria:\n\n* History or presence of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data\n* Abnormal blood pressure as determined by the investigator\n* Alanine transaminase (ALT) \\>1.5xupper limit of normal (ULN)\n* Bilirubin \\>1.5xULN (isolated bilirubin \\>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \\<35%)\n* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* Average corrected QT interval by Fridericia's formula (QTcF) \\>450 milliseconds (msec) (based on triplicate ECGs)\n* Participants who have asthma or a history of asthma (except in childhood and which has now remitted)\n* Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing. Specific concomitant medications listed in protocol may be allowed\n* Live vaccine(s) within 1 month prior to screening, or plans to receive such vaccines during the study\n* Participation in the study would result in loss of blood or blood products in excess of 500 milliliters (mL) within 56 days\n* Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day\n* Current enrolment or past participation within the last 90 days of exposure to any other clinical study involving an investigational study treatment or any other type of medical research\n* Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C antibody test result at screening\n* Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment\n* Positive pre-study drug/alcohol screen\n* Positive human immunodeficiency virus (HIV) antibody test\n* Regular use of known drugs of abuse\n* Regular alcohol consumption within 3 months prior to the study defined as: An average weekly intake of \\>14 units for males and females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits\n* Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study\n* Participants who are unable to produce a total weight of at least 100 milligrams (mg) of selected sputum during sputum induction at screening\n* Participants whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes and cigars", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Cambridge", "zip": "CB2 2GG", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}]}, "referencesModule": {"references": [{"pmid": "30940692", "type": "BACKGROUND", "citation": "Begg M, Edwards CD, Hamblin JN, Pefani E, Wilson R, Gilbert J, Vitulli G, Mallett D, Morrell J, Hingle MI, Uddin S, Ehtesham F, Marotti M, Harrell A, Newman CF, Fernando D, Clark J, Cahn A, Hessel EM. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase delta Inhibitor. J Pharmacol Exp Ther. 2019 Jun;369(3):443-453. doi: 10.1124/jpet.119.257311. Epub 2019 Apr 2."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "IPD for this study will be made available via the Clinical Study Data Request site.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR"], "timeFrame": "IPD is available via the Clinical Study Data Request site (click on the link provided below)", "accessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.", "url": "https://www.clinicalstudydatarequest.com/SearchAllPostings.aspx?searchparam=202062"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Part A comprised of two cohorts, each of which consisted of 3 treatment periods with 4 treatment sequences. Out of 98 screened participants, 37 were randomized, 58 were screen failures and 3 were retained as reserve participants. In Part B, 12 participants were included, 11 of them were taken from Part A and 1 additional participant only for Part B", "recruitmentDetails": "This is a two part, single site, randomized, double-blind (sponsor open), placebo controlled study in healthy smokers. Study was conducted in the United Kingdom.", "groups": [{"id": "FG000", "title": "Part A: Placebo/200 \u00b5g GSK2292767/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 1 were administered a single dose of placebo in Period 1, 200 \u00b5g GSK2292767 in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA Dry Powder Inhaler (DPI). There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG001", "title": "Part A:50 \u00b5g GSK2292767/Placebo/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 2 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, placebo in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG002", "title": "Part A:50 \u00b5g GSK2292767/200 \u00b5g GSK2292767/Placebo", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 3 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, 200 \u00b5g GSK2292767 in Period 2 and placebo in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG003", "title": "Part A:50 \u00b5g GSK2292767/200 \u00b5g GSK2292767/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 4 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, 200 \u00b5g GSK2292767 in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG004", "title": "Part A:Placebo/500 \u00b5g GSK2292767/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 5 were administered a single dose of placebo in Period 1, 500 \u00b5g GSK2292767 in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG005", "title": "Part A:100 \u00b5g GSK2292767/Placebo/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 6 were administered a single dose of 100 ug GSK2292767 in Period 1, placebo in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG006", "title": "Part A:100 \u00b5g GSK2292767/500 \u00b5g GSK2292767/Placebo", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 7 were administered a single dose of 100 \u00b5g GSK2292767 in Period 1, 500 \u00b5g GSK2292767 in Period 2 and placebo in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG007", "title": "Part A:100 \u00b5g GSK2292767/500 \u00b5g GSK2292767/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 8 were administered a single dose of 100 \u00b5g GSK2292767 in Period 1, 500 \u00b5g GSK2292767 in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI . There was a period of 4 weeks between doses for an individual participant."}, {"id": "FG008", "title": "Part B:Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "FG009", "title": "Part B:GSK2292767 2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "periods": [{"title": "Part A, Period (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Part A,Washout Period 1(4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Part A, Period 2 (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Part A,Washout Period 2 (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Part A, Period 3 (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "4"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Part B (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "3"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "3"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Data is presented for Part A and Part B. In Part B, 12 participants were included, 11 of them were taken from Part A and 1 additional participant only for Part B. Thus total number of participants included were 38 and not 49.", "groups": [{"id": "BG000", "title": "Part A:Placebo/200 \u00b5g GSK2292767/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 1 were administered a single dose of placebo in Period 1, 200 \u00b5g GSK2292767 in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA Dry Powder Inhaler (DPI). There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG001", "title": "Part A:50 \u00b5g GSK2292767/Placebo/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 2 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, placebo in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG002", "title": "Part A:50 \u00b5g GSK2292767/200 \u00b5g GSK2292767/Placebo", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 3 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, 200 \u00b5g GSK2292767 in Period 2 and placebo in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG003", "title": "Part A:50 \u00b5g GSK2292767/200 \u00b5g GSK2292767/1000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 4 were administered a single dose of 50 \u00b5g GSK2292767 in Period 1, 200 \u00b5g GSK2292767 in Period 2 and 1000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG004", "title": "Part A:Placebo/500 \u00b5g GSK2292767/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 5 were administered a single dose of placebo in Period 1, 500 \u00b5g GSK2292767 in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG005", "title": "Part A:100 \u00b5g GSK2292767/Placebo/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 6 were administered a single dose of 100 ug GSK2292767 in Period 1, placebo in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG006", "title": "Part A:100 \u00b5g GSK2292767/500 \u00b5g GSK2292767/Placebo", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 7 were administered a single dose of 100 \u00b5g GSK2292767 in Period 1, 500 \u00b5g GSK2292767 in Period 2 and placebo in Period 3. The treatment was administered via ELLIPTA DPI. There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG007", "title": "Part A:100 \u00b5g GSK2292767/500 \u00b5g GSK2292767/2000 \u00b5g GSK2292767", "description": "Part A consisted of two cohorts each containing three treatment periods with four treatment sequences. Participants randomized to Sequence 8 were administered a single dose of 100 \u00b5g GSK2292767 in Period 1, 500 \u00b5g GSK2292767 in Period 2 and 2000 \u00b5g GSK2292767 in Period 3. The treatment was administered via ELLIPTA DPI . There was a period of 4 weeks between doses for an individual participant."}, {"id": "BG008", "title": "Part B: Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "BG009", "title": "Part B: GSK2292767 2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "BG010", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "4"}, {"groupId": "BG008", "value": "3"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "49"}]}], "measures": [{"title": "Age, Categorical", "description": "All enrolled participants have been confirmed by site to have been at least 18 years at the time of screening. One participants has a derived age of 17 due to the way in which their partial birthdate was imputed.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "1"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "4"}, {"groupId": "BG008", "value": "3"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "48"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "4"}, {"groupId": "BG008", "value": "3"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "49"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "2"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "1"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "4"}, {"groupId": "BG008", "value": "3"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "46"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Part A: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE)", "description": "An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants with 5 percent nSAEs and SAEs has been reported.", "populationDescription": "Safety Population comprised of all randomized participants who took at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 12 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "nSAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "7"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "4"}, {"groupId": "OG006", "value": "5"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Number of Participants With Any AE and Any SAE", "description": "An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants with 5 percent nSAEs and SAEs has been reported.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "nSAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)", "description": "Blood pressure in part A was assessed in a semi supine position with a completely automated device. SBP and DBP measurements were preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "DBP, 30 min", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "6.66"}, {"groupId": "OG001", "value": "2.0", "spread": "6.48"}, {"groupId": "OG002", "value": "2.4", "spread": "4.91"}, {"groupId": "OG003", "value": "2.0", "spread": "5.23"}, {"groupId": "OG004", "value": "2.5", "spread": "6.20"}, {"groupId": "OG005", "value": "-1.6", "spread": "5.36"}, {"groupId": "OG006", "value": "1.9", "spread": "3.58"}]}]}, {"title": "DBP, 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "7.02"}, {"groupId": "OG001", "value": "3.1", "spread": "4.98"}, {"groupId": "OG002", "value": "3.8", "spread": "4.65"}, {"groupId": "OG003", "value": "1.2", "spread": "3.63"}, {"groupId": "OG004", "value": "4.1", "spread": "4.44"}, {"groupId": "OG005", "value": "-0.9", "spread": "7.72"}, {"groupId": "OG006", "value": "0.8", "spread": "5.04"}]}]}, {"title": "DBP, 6 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "5.48"}, {"groupId": "OG001", "value": "0.3", "spread": "7.41"}, {"groupId": "OG002", "value": "1.8", "spread": "3.84"}, {"groupId": "OG003", "value": "1.9", "spread": "7.04"}, {"groupId": "OG004", "value": "3.2", "spread": "6.22"}, {"groupId": "OG005", "value": "-2.0", "spread": "2.83"}, {"groupId": "OG006", "value": "3.1", "spread": "7.93"}]}]}, {"title": "DBP, 12 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "6.36"}, {"groupId": "OG001", "value": "3.1", "spread": "6.72"}, {"groupId": "OG002", "value": "2.9", "spread": "3.45"}, {"groupId": "OG003", "value": "4.0", "spread": "7.92"}, {"groupId": "OG004", "value": "2.3", "spread": "6.41"}, {"groupId": "OG005", "value": "0.7", "spread": "4.39"}, {"groupId": "OG006", "value": "3.1", "spread": "7.76"}]}]}, {"title": "DBP, 24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "6.81"}, {"groupId": "OG001", "value": "0.6", "spread": "6.32"}, {"groupId": "OG002", "value": "1.5", "spread": "3.90"}, {"groupId": "OG003", "value": "3.6", "spread": "8.03"}, {"groupId": "OG004", "value": "3.6", "spread": "4.21"}, {"groupId": "OG005", "value": "-2.9", "spread": "5.62"}, {"groupId": "OG006", "value": "-0.1", "spread": "5.12"}]}]}, {"title": "SBP, 30 min", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.2", "spread": "6.28"}, {"groupId": "OG001", "value": "-0.2", "spread": "5.06"}, {"groupId": "OG002", "value": "-3.9", "spread": "9.67"}, {"groupId": "OG003", "value": "0.8", "spread": "5.16"}, {"groupId": "OG004", "value": "-2.3", "spread": "6.20"}, {"groupId": "OG005", "value": "-6.1", "spread": "4.73"}, {"groupId": "OG006", "value": "-3.3", "spread": "5.85"}]}]}, {"title": "SBP, 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "7.72"}, {"groupId": "OG001", "value": "-1.5", "spread": "4.74"}, {"groupId": "OG002", "value": "-5.6", "spread": "8.07"}, {"groupId": "OG003", "value": "-3.4", "spread": "7.01"}, {"groupId": "OG004", "value": "-2.2", "spread": "6.53"}, {"groupId": "OG005", "value": "-7.1", "spread": "9.06"}, {"groupId": "OG006", "value": "-3.9", "spread": "8.38"}]}]}, {"title": "SBP, 6 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "8.79"}, {"groupId": "OG001", "value": "0.7", "spread": "8.23"}, {"groupId": "OG002", "value": "-3.8", "spread": "9.03"}, {"groupId": "OG003", "value": "4.5", "spread": "7.92"}, {"groupId": "OG004", "value": "2.8", "spread": "6.34"}, {"groupId": "OG005", "value": "-0.3", "spread": "7.48"}, {"groupId": "OG006", "value": "-0.8", "spread": "5.86"}]}]}, {"title": "SBP, 12 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "6.65"}, {"groupId": "OG001", "value": "3.3", "spread": "6.52"}, {"groupId": "OG002", "value": "-1.3", "spread": "8.65"}, {"groupId": "OG003", "value": "3.6", "spread": "4.93"}, {"groupId": "OG004", "value": "5.0", "spread": "9.53"}, {"groupId": "OG005", "value": "1.6", "spread": "4.03"}, {"groupId": "OG006", "value": "3.3", "spread": "7.33"}]}]}, {"title": "SBP, 24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "6.19"}, {"groupId": "OG001", "value": "-0.9", "spread": "7.54"}, {"groupId": "OG002", "value": "-5.3", "spread": "5.26"}, {"groupId": "OG003", "value": "0.0", "spread": "8.67"}, {"groupId": "OG004", "value": "-1.5", "spread": "6.78"}, {"groupId": "OG005", "value": "-4.3", "spread": "5.74"}, {"groupId": "OG006", "value": "-2.8", "spread": "5.77"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Change From Baseline in SBP and DBP", "description": "Blood pressure in part B were assessed in semi supine position with a completely automated device. SBP and DBP preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "DBP, Day 2, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.0", "spread": "10.15"}, {"groupId": "OG001", "value": "-3.0", "spread": "4.72"}]}]}, {"title": "DBP, Day 3, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3", "spread": "9.45"}, {"groupId": "OG001", "value": "-1.3", "spread": "5.85"}]}]}, {"title": "DBP, Day 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.3", "spread": "12.10"}, {"groupId": "OG001", "value": "-3.4", "spread": "4.90"}]}]}, {"title": "DBP, Day 5, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.7", "spread": "11.72"}, {"groupId": "OG001", "value": "-2.2", "spread": "5.09"}]}]}, {"title": "DBP, Day 6, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.7", "spread": "10.02"}, {"groupId": "OG001", "value": "-3.7", "spread": "4.72"}]}]}, {"title": "DBP, Day 7, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3", "spread": "9.45"}, {"groupId": "OG001", "value": "-2.3", "spread": "3.57"}]}]}, {"title": "DBP, Day 8, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.7", "spread": "12.42"}, {"groupId": "OG001", "value": "-4.3", "spread": "3.91"}]}]}, {"title": "DBP, Day 9, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.3", "spread": "11.93"}, {"groupId": "OG001", "value": "-2.8", "spread": "4.02"}]}]}, {"title": "DBP, Day 10, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.7", "spread": "11.93"}, {"groupId": "OG001", "value": "-0.6", "spread": "6.21"}]}]}, {"title": "DBP, Day 11, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "12.74"}, {"groupId": "OG001", "value": "-2.1", "spread": "4.46"}]}]}, {"title": "DBP, Day 12, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.3", "spread": "7.51"}, {"groupId": "OG001", "value": "-2.9", "spread": "4.23"}]}]}, {"title": "DBP, Day 13, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.0", "spread": "10.58"}, {"groupId": "OG001", "value": "-3.0", "spread": "5.43"}]}]}, {"title": "DBP, Day 14, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.3", "spread": "10.97"}, {"groupId": "OG001", "value": "-3.2", "spread": "3.83"}]}]}, {"title": "DBP, Day 14, 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "1.53"}, {"groupId": "OG001", "value": "-1.0", "spread": "5.17"}]}]}, {"title": "SBP, Day 2, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "11.24"}, {"groupId": "OG001", "value": "-5.4", "spread": "7.60"}]}]}, {"title": "SBP, Day 3, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "9.07"}, {"groupId": "OG001", "value": "-0.1", "spread": "8.70"}]}]}, {"title": "SBP, Day 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "10.50"}, {"groupId": "OG001", "value": "-4.1", "spread": "7.75"}]}]}, {"title": "SBP, Day 5, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "9.85"}, {"groupId": "OG001", "value": "-5.1", "spread": "8.74"}]}]}, {"title": "SBP, Day 6, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "8.50"}, {"groupId": "OG001", "value": "-7.2", "spread": "7.26"}]}]}, {"title": "SBP, Day 7, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.7", "spread": "5.86"}, {"groupId": "OG001", "value": "-5.0", "spread": "9.50"}]}]}, {"title": "SBP, Day 8, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "8.08"}, {"groupId": "OG001", "value": "-7.6", "spread": "10.01"}]}]}, {"title": "SBP, Day 9, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "3.61"}, {"groupId": "OG001", "value": "-5.8", "spread": "4.27"}]}]}, {"title": "SBP, Day 10, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.7", "spread": "5.13"}, {"groupId": "OG001", "value": "-5.2", "spread": "6.65"}]}]}, {"title": "SBP, Day 11, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.3", "spread": "5.51"}, {"groupId": "OG001", "value": "-4.4", "spread": "9.06"}]}]}, {"title": "SBP, Day 12, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.3", "spread": "4.73"}, {"groupId": "OG001", "value": "-5.4", "spread": "6.54"}]}]}, {"title": "SBP, Day 13, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.3", "spread": "4.93"}, {"groupId": "OG001", "value": "-4.9", "spread": "6.51"}]}]}, {"title": "SBP, Day 14, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "7.57"}, {"groupId": "OG001", "value": "-4.6", "spread": "7.33"}]}]}, {"title": "SBP, Day 14, 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "2.08"}, {"groupId": "OG001", "value": "-3.7", "spread": "6.71"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Change From Baseline in Heart Rate", "description": "Heart rate in part A was assessed in a semi supine position with a completely automated device. Heart rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "30 min", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.3", "spread": "5.39"}, {"groupId": "OG001", "value": "-5.8", "spread": "5.40"}, {"groupId": "OG002", "value": "-8.9", "spread": "8.46"}, {"groupId": "OG003", "value": "-6.1", "spread": "5.25"}, {"groupId": "OG004", "value": "-6.3", "spread": "5.37"}, {"groupId": "OG005", "value": "-12.4", "spread": "6.80"}, {"groupId": "OG006", "value": "-6.1", "spread": "7.24"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.0", "spread": "5.60"}, {"groupId": "OG001", "value": "-4.8", "spread": "3.57"}, {"groupId": "OG002", "value": "-9.0", "spread": "8.90"}, {"groupId": "OG003", "value": "-7.2", "spread": "5.27"}, {"groupId": "OG004", "value": "-4.3", "spread": "7.63"}, {"groupId": "OG005", "value": "-13.0", "spread": "7.98"}, {"groupId": "OG006", "value": "-9.8", "spread": "7.55"}]}]}, {"title": "6 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "9.45"}, {"groupId": "OG001", "value": "4.3", "spread": "5.58"}, {"groupId": "OG002", "value": "1.0", "spread": "9.55"}, {"groupId": "OG003", "value": "4.9", "spread": "5.42"}, {"groupId": "OG004", "value": "7.4", "spread": "6.37"}, {"groupId": "OG005", "value": "-1.3", "spread": "7.42"}, {"groupId": "OG006", "value": "2.4", "spread": "7.98"}]}]}, {"title": "12 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "spread": "7.11"}, {"groupId": "OG001", "value": "6.4", "spread": "7.80"}, {"groupId": "OG002", "value": "-0.3", "spread": "10.17"}, {"groupId": "OG003", "value": "3.7", "spread": "6.24"}, {"groupId": "OG004", "value": "3.7", "spread": "5.85"}, {"groupId": "OG005", "value": "-1.8", "spread": "8.61"}, {"groupId": "OG006", "value": "5.3", "spread": "10.38"}]}]}, {"title": "24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "6.24"}, {"groupId": "OG001", "value": "-1.7", "spread": "6.69"}, {"groupId": "OG002", "value": "-1.8", "spread": "8.70"}, {"groupId": "OG003", "value": "-3.0", "spread": "7.23"}, {"groupId": "OG004", "value": "-1.8", "spread": "8.02"}, {"groupId": "OG005", "value": "-6.9", "spread": "5.88"}, {"groupId": "OG006", "value": "-4.0", "spread": "8.18"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Change From Baseline in Heart Rate", "description": "Heart rate in part B was assessed in a semi supine position with a completely automated device. Heart rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Day 2, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "6.11"}, {"groupId": "OG001", "value": "-0.7", "spread": "7.14"}]}]}, {"title": "Day 3, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "6.56"}, {"groupId": "OG001", "value": "0.0", "spread": "6.76"}]}]}, {"title": "Day 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.7", "spread": "11.50"}, {"groupId": "OG001", "value": "-2.2", "spread": "8.03"}]}]}, {"title": "Day 5, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "9.45"}, {"groupId": "OG001", "value": "-3.2", "spread": "9.26"}]}]}, {"title": "Day 6, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "8.14"}, {"groupId": "OG001", "value": "-6.4", "spread": "7.80"}]}]}, {"title": "Day 7, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "9.07"}, {"groupId": "OG001", "value": "-0.8", "spread": "11.12"}]}]}, {"title": "Day 8, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "13.50"}, {"groupId": "OG001", "value": "-3.2", "spread": "5.85"}]}]}, {"title": "Day 9, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "5.13"}, {"groupId": "OG001", "value": "-3.4", "spread": "8.49"}]}]}, {"title": "Day 10, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "11.79"}, {"groupId": "OG001", "value": "-2.7", "spread": "10.28"}]}]}, {"title": "Day 11, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "14.64"}, {"groupId": "OG001", "value": "-2.8", "spread": "11.98"}]}]}, {"title": "Day 12, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.7", "spread": "7.23"}, {"groupId": "OG001", "value": "-4.9", "spread": "6.47"}]}]}, {"title": "Day 13, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.0", "spread": "15.00"}, {"groupId": "OG001", "value": "-4.4", "spread": "6.13"}]}]}, {"title": "Day 14, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.0", "spread": "11.27"}, {"groupId": "OG001", "value": "-5.8", "spread": "9.36"}]}]}, {"title": "Day 14, 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "7.57"}, {"groupId": "OG001", "value": "-2.2", "spread": "7.56"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Change From Baseline in Respiratory Rate", "description": "Respiratory rate in part A was assessed in a semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Breaths per minute", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "30 min", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "1.78"}, {"groupId": "OG001", "value": "-1.1", "spread": "2.81"}, {"groupId": "OG002", "value": "-1.5", "spread": "1.98"}, {"groupId": "OG003", "value": "0.8", "spread": "2.48"}, {"groupId": "OG004", "value": "0.3", "spread": "2.01"}, {"groupId": "OG005", "value": "0.3", "spread": "2.74"}, {"groupId": "OG006", "value": "-0.2", "spread": "1.95"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "2.27"}, {"groupId": "OG001", "value": "-1.0", "spread": "2.76"}, {"groupId": "OG002", "value": "-1.2", "spread": "2.17"}, {"groupId": "OG003", "value": "0.8", "spread": "2.03"}, {"groupId": "OG004", "value": "0.6", "spread": "2.23"}, {"groupId": "OG005", "value": "-0.3", "spread": "2.35"}, {"groupId": "OG006", "value": "-0.8", "spread": "2.41"}]}]}, {"title": "6 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "2.18"}, {"groupId": "OG001", "value": "0.0", "spread": "3.67"}, {"groupId": "OG002", "value": "1.0", "spread": "1.95"}, {"groupId": "OG003", "value": "1.0", "spread": "2.97"}, {"groupId": "OG004", "value": "0.8", "spread": "3.33"}, {"groupId": "OG005", "value": "0.6", "spread": "2.74"}, {"groupId": "OG006", "value": "0.3", "spread": "2.23"}]}]}, {"title": "12 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "2.31"}, {"groupId": "OG001", "value": "0.7", "spread": "3.11"}, {"groupId": "OG002", "value": "-0.4", "spread": "2.43"}, {"groupId": "OG003", "value": "1.3", "spread": "2.14"}, {"groupId": "OG004", "value": "0.6", "spread": "2.75"}, {"groupId": "OG005", "value": "0.3", "spread": "2.55"}, {"groupId": "OG006", "value": "-0.3", "spread": "1.86"}]}]}, {"title": "24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "2.29"}, {"groupId": "OG001", "value": "-0.9", "spread": "3.20"}, {"groupId": "OG002", "value": "-1.0", "spread": "2.63"}, {"groupId": "OG003", "value": "0.4", "spread": "2.50"}, {"groupId": "OG004", "value": "-0.8", "spread": "2.08"}, {"groupId": "OG005", "value": "-0.8", "spread": "3.15"}, {"groupId": "OG006", "value": "-0.4", "spread": "1.68"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Change From Baseline in Respiratory Rate", "description": "Respiratory rate in part B was assessed in a semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Breaths per minute", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Day 2, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "0.58"}, {"groupId": "OG001", "value": "-0.6", "spread": "3.17"}]}]}, {"title": "Day 3, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "2.31"}, {"groupId": "OG001", "value": "-1.0", "spread": "3.20"}]}]}, {"title": "Day 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "2.08"}, {"groupId": "OG001", "value": "-0.3", "spread": "2.96"}]}]}, {"title": "Day 5, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "2.31"}, {"groupId": "OG001", "value": "-1.4", "spread": "2.65"}]}]}, {"title": "Day 6, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "0.58"}, {"groupId": "OG001", "value": "-1.6", "spread": "2.92"}]}]}, {"title": "Day 7, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "2.31"}, {"groupId": "OG001", "value": "-0.8", "spread": "2.59"}]}]}, {"title": "Day 8, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "0.58"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.45"}]}]}, {"title": "Day 9, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "2.00"}, {"groupId": "OG001", "value": "0.1", "spread": "2.98"}]}]}, {"title": "Day 10, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "2.31"}, {"groupId": "OG001", "value": "-1.2", "spread": "2.54"}]}]}, {"title": "Day 11, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.3", "spread": "0.58"}, {"groupId": "OG001", "value": "-0.9", "spread": "3.62"}]}]}, {"title": "Day 12, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "1.15"}, {"groupId": "OG001", "value": "-1.0", "spread": "2.74"}]}]}, {"title": "Day 13, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "1.15"}, {"groupId": "OG001", "value": "-0.1", "spread": "3.06"}]}]}, {"title": "Day 14, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "1.73"}, {"groupId": "OG001", "value": "-1.1", "spread": "2.89"}]}]}, {"title": "Day 14, 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "1.53"}, {"groupId": "OG001", "value": "-1.1", "spread": "2.26"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Change From Baseline in Tympanic Temperature", "description": "Tympanic temperature in part A was assessed in semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Celsius", "timeFrame": "Baseline, 30 minutes, 1, 6, 12 and 24 hours post-dose in each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "30 min", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.313"}, {"groupId": "OG001", "value": "0.07", "spread": "0.210"}, {"groupId": "OG002", "value": "0.04", "spread": "0.574"}, {"groupId": "OG003", "value": "0.05", "spread": "0.395"}, {"groupId": "OG004", "value": "-0.05", "spread": "0.366"}, {"groupId": "OG005", "value": "0.03", "spread": "0.287"}, {"groupId": "OG006", "value": "0.16", "spread": "0.385"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.348"}, {"groupId": "OG001", "value": "0.06", "spread": "0.173"}, {"groupId": "OG002", "value": "0.05", "spread": "0.498"}, {"groupId": "OG003", "value": "-0.06", "spread": "0.287"}, {"groupId": "OG004", "value": "0.05", "spread": "0.478"}, {"groupId": "OG005", "value": "0.12", "spread": "0.311"}, {"groupId": "OG006", "value": "0.10", "spread": "0.449"}]}]}, {"title": "6 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "0.390"}, {"groupId": "OG001", "value": "0.08", "spread": "0.259"}, {"groupId": "OG002", "value": "0.18", "spread": "0.566"}, {"groupId": "OG003", "value": "0.07", "spread": "0.446"}, {"groupId": "OG004", "value": "0.17", "spread": "0.409"}, {"groupId": "OG005", "value": "0.14", "spread": "0.361"}, {"groupId": "OG006", "value": "0.19", "spread": "0.493"}]}]}, {"title": "12 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.478"}, {"groupId": "OG001", "value": "0.31", "spread": "0.370"}, {"groupId": "OG002", "value": "0.27", "spread": "0.542"}, {"groupId": "OG003", "value": "0.26", "spread": "0.355"}, {"groupId": "OG004", "value": "0.20", "spread": "0.591"}, {"groupId": "OG005", "value": "0.46", "spread": "0.400"}, {"groupId": "OG006", "value": "0.18", "spread": "0.622"}]}]}, {"title": "24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.375"}, {"groupId": "OG001", "value": "-0.02", "spread": "0.233"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.513"}, {"groupId": "OG003", "value": "0.03", "spread": "0.287"}, {"groupId": "OG004", "value": "0.07", "spread": "0.392"}, {"groupId": "OG005", "value": "0.11", "spread": "0.326"}, {"groupId": "OG006", "value": "0.02", "spread": "0.497"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Change From Baseline in Tympanic Temperature", "description": "Tympanic temperature in part B was assessed in semi supine position after 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as measurements done on Day -1. Change from Baseline was defined as the value at indicated time point minus Baseline value. Baseline was defined as latest pre-dose measurement. Change from Baseline was defined as the value at indicated time point minus Baseline value.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Celsius", "timeFrame": "Baseline, Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Day 2, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.058"}, {"groupId": "OG001", "value": "0.26", "spread": "0.477"}]}]}, {"title": "Day 3, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.379"}, {"groupId": "OG001", "value": "0.37", "spread": "0.450"}]}]}, {"title": "Day 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.153"}, {"groupId": "OG001", "value": "0.26", "spread": "0.416"}]}]}, {"title": "Day 5, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.404"}, {"groupId": "OG001", "value": "0.34", "spread": "0.445"}]}]}, {"title": "Day 6, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.265"}, {"groupId": "OG001", "value": "0.31", "spread": "0.322"}]}]}, {"title": "Day 7, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.100"}, {"groupId": "OG001", "value": "0.41", "spread": "0.448"}]}]}, {"title": "Day 8, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.27", "spread": "0.231"}, {"groupId": "OG001", "value": "0.29", "spread": "0.462"}]}]}, {"title": "Day 9, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.153"}, {"groupId": "OG001", "value": "0.21", "spread": "0.326"}]}]}, {"title": "Day 10, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.451"}, {"groupId": "OG001", "value": "0.31", "spread": "0.392"}]}]}, {"title": "Day 11, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.306"}, {"groupId": "OG001", "value": "0.34", "spread": "0.343"}]}]}, {"title": "Day 12, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.265"}, {"groupId": "OG001", "value": "0.32", "spread": "0.415"}]}]}, {"title": "Day 13, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.513"}, {"groupId": "OG001", "value": "0.33", "spread": "0.466"}]}]}, {"title": "Day 14, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.115"}, {"groupId": "OG001", "value": "0.32", "spread": "0.458"}]}]}, {"title": "Day 14, 24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.115"}, {"groupId": "OG001", "value": "0.32", "spread": "0.502"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry at the indicated time. FEV1 measurements were repeated until three technically acceptable measurements (within 150 milliliter \\[mL\\] of each other) were made. Data for FEV1 for part A is presented here.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Day 1 (pre-dose and 1 hour)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "Pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.389", "spread": "0.6781"}, {"groupId": "OG001", "value": "4.044", "spread": "0.6717"}, {"groupId": "OG002", "value": "4.768", "spread": "0.8348"}, {"groupId": "OG003", "value": "3.896", "spread": "0.7292"}, {"groupId": "OG004", "value": "4.288", "spread": "0.5288"}, {"groupId": "OG005", "value": "4.036", "spread": "0.4806"}, {"groupId": "OG006", "value": "4.391", "spread": "0.5072"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.347", "spread": "0.6781"}, {"groupId": "OG001", "value": "4.028", "spread": "0.7177"}, {"groupId": "OG002", "value": "4.461", "spread": "0.4693"}, {"groupId": "OG003", "value": "3.811", "spread": "0.6757"}, {"groupId": "OG004", "value": "4.223", "spread": "0.5153"}, {"groupId": "OG005", "value": "4.024", "spread": "0.5971"}, {"groupId": "OG006", "value": "4.435", "spread": "0.5851"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)", "description": "FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry at the indicated time. Existing spirometry equipment was used. FEV1 measurements were repeated until three technically acceptable measurements (within 150 mL of each other) were made. Data for FEV1 for part B is presented here.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Up to Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Day -1", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.333", "spread": "0.1739"}, {"groupId": "OG001", "value": "4.570", "spread": "0.6275"}]}]}, {"title": "Day 1,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.277", "spread": "0.0987"}, {"groupId": "OG001", "value": "4.408", "spread": "0.6852"}]}]}, {"title": "Day 1,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.323", "spread": "0.0981"}, {"groupId": "OG001", "value": "4.413", "spread": "0.6931"}]}]}, {"title": "Day 2,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.357", "spread": "0.0551"}, {"groupId": "OG001", "value": "4.446", "spread": "0.7230"}]}]}, {"title": "Day 2,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.373", "spread": "0.0569"}, {"groupId": "OG001", "value": "4.486", "spread": "0.6828"}]}]}, {"title": "Day 3,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.407", "spread": "0.1504"}, {"groupId": "OG001", "value": "4.474", "spread": "0.6999"}]}]}, {"title": "Day 3,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.460", "spread": "0.2771"}, {"groupId": "OG001", "value": "4.493", "spread": "0.6548"}]}]}, {"title": "Day 4,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.447", "spread": "0.1159"}, {"groupId": "OG001", "value": "4.483", "spread": "0.7241"}]}]}, {"title": "Day 4,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.307", "spread": "0.1060"}, {"groupId": "OG001", "value": "4.519", "spread": "0.7444"}]}]}, {"title": "Day 5,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.290", "spread": "0.1082"}, {"groupId": "OG001", "value": "4.494", "spread": "0.8042"}]}]}, {"title": "Day 5,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.480", "spread": "0.2600"}, {"groupId": "OG001", "value": "4.486", "spread": "0.7647"}]}]}, {"title": "Day 6,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.300", "spread": "0.0173"}, {"groupId": "OG001", "value": "4.498", "spread": "0.7086"}]}]}, {"title": "Day 6,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.533", "spread": "0.3177"}, {"groupId": "OG001", "value": "4.573", "spread": "0.7994"}]}]}, {"title": "Day 7,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.467", "spread": "0.2386"}, {"groupId": "OG001", "value": "4.503", "spread": "0.8559"}]}]}, {"title": "Day 7,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.400", "spread": "0.2207"}, {"groupId": "OG001", "value": "4.581", "spread": "0.8018"}]}]}, {"title": "Day 8,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.383", "spread": "0.0351"}, {"groupId": "OG001", "value": "4.449", "spread": "0.7952"}]}]}, {"title": "Day 8,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.440", "spread": "0.1229"}, {"groupId": "OG001", "value": "4.572", "spread": "0.6952"}]}]}, {"title": "Day 9,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.483", "spread": "0.2458"}, {"groupId": "OG001", "value": "4.512", "spread": "0.7483"}]}]}, {"title": "Day 9,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.470", "spread": "0.1179"}, {"groupId": "OG001", "value": "4.627", "spread": "0.7737"}]}]}, {"title": "Day 10,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.443", "spread": "0.1419"}, {"groupId": "OG001", "value": "4.473", "spread": "0.6942"}]}]}, {"title": "Day 10,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.583", "spread": "0.1914"}, {"groupId": "OG001", "value": "4.582", "spread": "0.7609"}]}]}, {"title": "Day 11,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.423", "spread": "0.1422"}, {"groupId": "OG001", "value": "4.570", "spread": "0.7944"}]}]}, {"title": "Day 11,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.463", "spread": "0.2540"}, {"groupId": "OG001", "value": "4.609", "spread": "0.7460"}]}]}, {"title": "Day 12,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.417", "spread": "0.1258"}, {"groupId": "OG001", "value": "4.599", "spread": "0.7469"}]}]}, {"title": "Day 12,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.440", "spread": "0.0917"}, {"groupId": "OG001", "value": "4.600", "spread": "0.7029"}]}]}, {"title": "Day 13,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.400", "spread": "0.2252"}, {"groupId": "OG001", "value": "4.514", "spread": "0.7352"}]}]}, {"title": "Day 13,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.653", "spread": "0.2146"}, {"groupId": "OG001", "value": "4.768", "spread": "0.7609"}]}]}, {"title": "Day 14,pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.533", "spread": "0.0666"}, {"groupId": "OG001", "value": "4.541", "spread": "0.8512"}]}]}, {"title": "Day 14,1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.557", "spread": "0.1701"}, {"groupId": "OG001", "value": "4.609", "spread": "0.8102"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Forced Vital Capacity (FVC)", "description": "FVC is a measure of lung function and is defined as total amount of air that can be exhaled during FEV1 test. FVC was planned to measured using spirometry. The FVC need to be normal at screening and is part of the Forced Expiratory ratio (FEV1/FVC) which should lie between 0.7-0.8 to indicate no chronic obstruction or restriction. The FVC was therefore only used at screening and requires no ongoing analysis during the study. All other indications of obstruction in the study, e.g. paradoxical bronchospasm was provided by the FEV1. The FVC therefore require no analysis.", "populationDescription": "Safety Population. Data was not collected for this outcome as FVC was used only at screening and no further analysis during the study was required.", "reportingStatus": "POSTED", "timeFrame": "Day 1 (pre-dose and 1 hour)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part B: Forced Vital Capacity (FVC)", "description": "FVC is a measure of lung function and is defined as total amount of air that can be exhaled during FEV1 test. FVC was planned to measured using spirometry. The FVC need to be normal at screening and is part of the Forced Expiratory ratio (FEV1/FVC) which should lie between 0.7-0.8 to indicate no chronic obstruction or restriction. The FVC was therefore only used at screening and requires no ongoing analysis during the study. All other indications of obstruction in the study, e.g. paradoxical bronchospasm was provided by the FEV1. The FVC therefore require no analysis.", "populationDescription": "Safety Population. Data was not collected for this outcome as FVC was used only at screening and no further analysis during the study was required.", "reportingStatus": "POSTED", "timeFrame": "Day 1 (pre-dose and 1 hour)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part A: Number of Participants With Electrocardiogram (ECG) Abnormalities", "description": "Triplicate/Single 12-lead ECG was obtained using an automated ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTFc intervals. Number of participants with abnormal clinically significant and abnormal-not clinically significant values at any time post-Baseline is presented.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 1 of each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "Abnormal - not clinically significant", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}]}]}, {"title": "Abnormal - clinically significant", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Number of Participants With ECG Abnormalities", "description": "Triplicate/Single 12-lead ECG was obtained using an automated ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTFc intervals. Number of participants with abnormal clinically significant and abnormal-not clinically significant values at any time post-Baseline is presented.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Pre-dose on Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Abnormal - not clinically significant", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Abnormal - clinically significant", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Number of Participants With Clinical Chemistry Values of Potential Clinical Importance Criteria (PCC)", "description": "Number of participants with clinical chemistry values that changed from normal to high or low in part A are presented. Chemistry parameters for which PCC values were identified were: Alkaline Phosphatase, Alanine Amino Transferase, aspartate aminotransferase, Total Bilirubin, calcium, glucose, potassium and Sodium.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 hours post-dose in each treatment period.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "Alkaline Phosphatase; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Alanine Amino Transferase; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Total Bilirubin; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Calcium; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Calcium; to low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Glucose; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Glucose; to low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Potassium; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Potassium; to low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Sodium; to high", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Sodium; to low", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Number of Participants With Clinical Chemistry Values of PCC", "description": "Number of participants with clinical chemistry values that changed from normal to high or low in part B are presented. Chemistry parameters for which PCC values were identified were: Alkaline Phosphatase, Alanine Amino Transferase, aspartate aminotransferase, Total Bilirubin, calcium, glucose, potassium and Sodium. Only participants with data available at specified time points were analyzed (represented by n=X in category titles)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Pre-dose on Days 2, 4, 6, 8, 10, 12, and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Alkaline Phosphatase,Day 2;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 14,pre-dose;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase,Day 14,24 hour;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 2;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 14,pre dose;to n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Amino Transferase,Day 14,24 hour;to hn=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 2;to high,n=3,8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 14,pre dose;n=2,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Amino Transferase,Day 14,24 hour,n=3,8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 2,;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 14,pre dose,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin,Day 14,24 hours,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 2;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 2;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 4;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 6;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 8;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 10;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 12;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 14,pre dose,to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 14,pre dose,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 14,24 hour,to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Calcium,Day 14,24 hour,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 2;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 2;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 4;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 6;to low, n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 8;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 10;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 10;to low,,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 12;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 12;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 14;pre dose,to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 14;pre dose,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 14;24 hours,to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Glucose,Day 14;24 hours,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 2;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 2;to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 4;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 4,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 6;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 6,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 8;to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 8, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 10;to high,,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 10,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 12;to high,,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 12,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 14,pre dose,to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 14,pre dose,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 14,24 hour ,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Potassium,Day 14,24 hour,to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 2, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 2, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 4, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 4, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 6, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 6, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 8, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 8, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 10, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 10, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 12, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 12, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 14,pre dose, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 14,pre dose, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 14,24 hour, to high,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Sodium,Day 14,24 hour, to low,n=3,9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part A: Number of Participants With Hematology Values of PCC", "description": "Number of participants with hematology parameters of PCC which shifted from normal to high in part A are presented. Hematology parameters for which PCC values were identified were: Hemoglobin, Hematocrit, Lymphocytes, Total Neutrophils, Platelet count and White Blood Cell (WBC) Count. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 hours post-dose in each treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route."}, {"id": "OG001", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG006", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "classes": [{"title": "Hemoglobin; to high,n=23,12,12,13,12,9,12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Hematocrit; to high,n=23,12,12,13,12,9,12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Lymphocytes; to low,n=23,12,12,13,12,9,12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Total Neutrophils; to low,n=23,12,12,13,12,9,12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Platelet count;to high;n=23, 12, 11, 13, 11, 9, 11", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "Platelet count; to low;n=23, 12, 11, 13, 11, 9, 11", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "WBC count,to high,n=23, 12, 12, 13, 12, 9, 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}, {"title": "WBC count,to low,n=23, 12, 12, 13, 12, 9, 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Part B: Number of Participants With Hematology Values of PCC", "description": "Number of participants with hematology parameters of PCC which shifted from normal to high in part B are presented. Hematology parameters for which PCC values were identified were: Hemoglobin, Hematocrit, Lymphocytes, Total Neutrophils, Platelet count and WBC count", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Pre-dose on Days 2, 4, 6, 8, 10, 12, and 14, 24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Hemoglobin,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemoglobin,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Lymphocytes,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Neutrophils,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelet count,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 14,pre dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WBC count,Day 14,24 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK2292767 for part A is presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). Pharmacokinetic population comprised of participants in the 'All participant' population for whom a pharmacokinetic sample was obtained and analyzed.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours*picograms per milliliter", "timeFrame": "Pre-dose (5 minutes (min), 30 min, 45 min, 1 hour (hr), 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods", "groups": [{"id": "OG000", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "9"}, {"groupId": "OG005", "value": "12"}]}], "classes": [{"title": "AUC (0-24);n=0,2,5,10,8,11", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "8"}, {"groupId": "OG005", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "596.1161", "spread": "10.0"}, {"groupId": "OG002", "value": "721.9301", "spread": "57.9"}, {"groupId": "OG003", "value": "2460.3695", "spread": "70.3"}, {"groupId": "OG004", "value": "3689.7545", "spread": "36.0"}, {"groupId": "OG005", "value": "7781.2593", "spread": "52.5"}]}]}, {"title": "AUC(0-inf);n=0,2,5,7,6,10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "7"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "596.4042", "spread": "10.1"}, {"groupId": "OG002", "value": "724.6058", "spread": "57.8"}, {"groupId": "OG003", "value": "2211.9120", "spread": "81.5"}, {"groupId": "OG004", "value": "3709.6509", "spread": "40.6"}, {"groupId": "OG005", "value": "8383.6427", "spread": "57.8"}]}]}, {"title": "AUC (0-t);n=12,12,12,12,9,12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "9"}, {"groupId": "OG005", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "69.5822", "spread": "133.1"}, {"groupId": "OG001", "value": "337.0775", "spread": "48.3"}, {"groupId": "OG002", "value": "633.3267", "spread": "59.6"}, {"groupId": "OG003", "value": "2164.3817", "spread": "72.3"}, {"groupId": "OG004", "value": "3440.6354", "spread": "37.1"}, {"groupId": "OG005", "value": "7758.9831", "spread": "50.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "0.41", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "0.61", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.243", "estimateComment": "AUC(0-t). Standard error of mean was on logged scale"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "0.98", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.65", "ciUpperLimit": "1.47", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.243", "estimateComment": "AUC(0-t).Standard error of mean was on logged scale"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "1.33", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.01", "ciUpperLimit": "1.74", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.161", "estimateComment": "AUC(0-t).Standard error of mean was on logged scale"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "1.06", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "1.62", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.255", "estimateComment": "AUC(0-t).Standard error of mean was on logged scale"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "1.25", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.95", "ciUpperLimit": "1.64", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.161", "estimateComment": "AUC(0-t).Standard error of mean was on logged scale"}]}, {"type": "SECONDARY", "title": "Part B: AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK2292767 for part B is presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).", "populationDescription": "Pharmacokinetic population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours*picograms per milliliter", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "AUC (0-24); Day 1; n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8163.4986", "spread": "71.7"}]}]}, {"title": "AUC (0-24); Day 14; n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9941.5681", "spread": "53.5"}]}]}, {"title": "AUC(0-inf); Day 1; n=7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10162.0636", "spread": "66.1"}]}]}, {"title": "AUC(0-inf);Day 14; n=7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13798.7637", "spread": "66.7"}]}]}, {"title": "AUC (0-t); Day 1; n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7506.5587", "spread": "72.3"}]}]}, {"title": "AUC (0-t); Day 14; n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11861.0783", "spread": "59.5"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "1.22", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.01", "ciUpperLimit": "1.47", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098", "estimateComment": "Treatment ratio of adjusted geometric mean (Day 14/Day 1) for AUC(0-24) is presented"}]}, {"type": "SECONDARY", "title": "Part A: Maximum Observed Plasma Drug Concentration (Cmax) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Five min post dose concentrations on Days 2-13 were assumed to be the Cmax values. Data for Cmax of GSK2292767 for part A is presented. Cmax is defined as maximum observed plasma concentration of GSK2292767.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picograms per milliliter", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods", "groups": [{"id": "OG000", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "9"}, {"groupId": "OG005", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.9018", "spread": "31.9"}, {"groupId": "OG001", "value": "90.8927", "spread": "30.6"}, {"groupId": "OG002", "value": "170.7836", "spread": "43.7"}, {"groupId": "OG003", "value": "356.0719", "spread": "39.4"}, {"groupId": "OG004", "value": "579.8303", "spread": "39.5"}, {"groupId": "OG005", "value": "1325.3877", "spread": "44.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "0.78", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "0.99", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.145"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "0.96", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.22", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.145"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "0.81", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.68", "ciUpperLimit": "0.97", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.106"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "0.66", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.51", "ciUpperLimit": "0.86", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.154"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "0.76", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "0.90", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.106"}]}, {"type": "SECONDARY", "title": "Part B: Cmax of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Five minute post dose concentrations on Days 2-13 were assumed to be the Cmax values. Data for Cmax of GSK2292767 for part B is presented.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picograms per milliliter", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1145.7369", "spread": "45.9"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "804.0363", "spread": "40.9"}]}]}, {"title": "Day 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "871.6343", "spread": "38.0"}]}]}, {"title": "Day 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "836.4375", "spread": "36.0"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "764.7799", "spread": "35.5"}]}]}, {"title": "Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "785.9632", "spread": "49.0"}]}]}, {"title": "Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "877.1960", "spread": "37.7"}]}]}, {"title": "Day 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "780.2829", "spread": "42.0"}]}]}, {"title": "Day 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "745.6613", "spread": "35.2"}]}]}, {"title": "Day 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "829.2395", "spread": "41.8"}]}]}, {"title": "Day 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "952.5536", "spread": "40.1"}]}]}, {"title": "Day 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "881.2328", "spread": "46.0"}]}]}, {"title": "Day 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "888.9151", "spread": "42.9"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "1305.8068", "spread": "41.9"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "paramType": "ratio", "paramValue": "1.14", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "1.36", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.104", "estimateComment": "Treatment ratio of adjusted geometric mean (Day 14/Day 1) for Cmax is presented"}]}, {"type": "SECONDARY", "title": "Part A: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Tmax of GSK2292767 for part A is presented.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods", "groups": [{"id": "OG000", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "9"}, {"groupId": "OG005", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0046", "lowerLimit": "0.083", "upperLimit": "3.006"}, {"groupId": "OG001", "value": "0.7540", "lowerLimit": "0.086", "upperLimit": "4.002"}, {"groupId": "OG002", "value": "0.7500", "lowerLimit": "0.085", "upperLimit": "3.006"}, {"groupId": "OG003", "value": "0.7583", "lowerLimit": "0.085", "upperLimit": "4.001"}, {"groupId": "OG004", "value": "1.0264", "lowerLimit": "0.509", "upperLimit": "2.000"}, {"groupId": "OG005", "value": "1.0125", "lowerLimit": "0.502", "upperLimit": "3.010"}]}]}]}, {"type": "SECONDARY", "title": "Part B: Tmax of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Tmax of GSK2292767 for part B is presented.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0056", "lowerLimit": "0.083", "upperLimit": "4.004"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0050", "lowerLimit": "0.085", "upperLimit": "3.008"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Terminal Half-life (T1/2) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for T1/2 of GSK2292767 for part A is presented. T1/2 is defined as the time required for one half of the total amount of a particular substance in a biological system to be degraded by biological processes. Only those participants with data available at the specified time points were analyzed.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose (5 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, and 24 hr post dose in each of the 3 treatment periods", "groups": [{"id": "OG000", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "7"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "1.6658", "spread": "32.1"}, {"groupId": "OG002", "value": "2.3157", "spread": "16.9"}, {"groupId": "OG003", "value": "3.9789", "spread": "57.6"}, {"groupId": "OG004", "value": "3.1712", "spread": "30.2"}, {"groupId": "OG005", "value": "6.3179", "spread": "35.8"}]}]}]}, {"type": "SECONDARY", "title": "Part B: T1/2 of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for T1/2 of GSK2292767 for part B is presented. T1/2 was defined as the time required for one half of the total amount of a particular substance in a biological system to be degraded by biological processes. Only those participants with data available at the specified time points were analyzed.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.4625", "spread": "35.0"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.7665", "spread": "48.6"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Trough Concentrations (Ctau) of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Ctau of GSK2292767 for part A is presented. Ctau is defined as the lowest concentration reached by a drug before the next dose is administered.", "populationDescription": "Pharmacokinetic population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picograms per milliliter", "timeFrame": "24 hr post dose in each of the 3 treatment periods", "groups": [{"id": "OG000", "title": "50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG001", "title": "100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG002", "title": "200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG003", "title": "500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG004", "title": "1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}, {"id": "OG005", "title": "2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "3"}, {"groupId": "OG005", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG003", "value": "43.5566", "spread": "65.9"}, {"groupId": "OG004", "value": "44.1985", "spread": "46.4"}, {"groupId": "OG005", "value": "71.6727", "spread": "55.6"}]}]}]}, {"type": "SECONDARY", "title": "Part B: Ctau of GSK2292767", "description": "Blood samples were collected for pharmacokinetic analysis of GSK2292767 at the specified time points. Data for Ctau of GSK2292767 for part B is presented. Ctau is defined as the lowest concentration reached by a drug before the next dose is administered. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Pico grams per milliliter", "timeFrame": "Pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 1; pre-dose, 5 minutes, 30 minutes, 45 minutes, 1, 2, 3, 4, 6, 8 and 12hours post dose on Day 14", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "Day 1;n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "78.4862", "spread": "91.4"}]}]}, {"title": "Day 2;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "103.4247", "spread": "83.8"}]}]}, {"title": "Day 3;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "98.3515", "spread": "84.1"}]}]}, {"title": "Day 4;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "112.5132", "spread": "83.4"}]}]}, {"title": "Day 5;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "98.4430", "spread": "87.6"}]}]}, {"title": "Day 6;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "106.6896", "spread": "96.2"}]}]}, {"title": "Day 7;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "101.1219", "spread": "88.3"}]}]}, {"title": "Day 8;n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "116.9160", "spread": "62.4"}]}]}, {"title": "Day 9;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "105.3676", "spread": "81.7"}]}]}, {"title": "Day 10;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "117.8348", "spread": "80.5"}]}]}, {"title": "Day 11;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "112.3146", "spread": "66.4"}]}]}, {"title": "Day 12;n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "129.6370", "spread": "62.8"}]}]}, {"title": "Day 13;n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "154.5480", "spread": "52.6"}]}]}, {"title": "Day 14;n=9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "138.2161", "spread": "96.7"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "paramType": "Ratio", "paramValue": "2.06", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.67", "ciUpperLimit": "2.55", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.128", "estimateComment": "Treatment ratio of adjusted geometric mean (Day 14/Day 1) for Ctau is presented."}]}, {"type": "SECONDARY", "title": "Part B: Concentration of GSK2292767 in Bronchoalveolar Lavage (BAL)", "description": "BAL samples were collected by bronchoscopy.", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picograms per milliliter", "timeFrame": "Day 15", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8852.94", "spread": "236.8"}]}]}]}, {"type": "SECONDARY", "title": "Part B: Concentration of GSK2292767 in Lung Epithelial Lining Fluid (ELF)", "description": "ELF from the lung was extracted from BAL samples. ELF drug concentration was calculated as BAL fluid drug concentration multiplied by dilution factor where dilution factor = Plasma urea (pre-bronchoscopy) divided by BAL urea. NA indicates data not available. Only participants with data available at specified time points were analyzed (represented by n=X in category titles).", "populationDescription": "Pharmacokinetic Population", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picograms per milliliters", "timeFrame": "Day 15", "groups": [{"id": "OG000", "title": "2000 \u00b5g OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "24 Hr Wash 1,n=0", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "24 Hr Wash 2,n=8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9777.25", "spread": "290.8"}]}]}, {"title": "24 Hr Wash 3,n=7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11921.13", "spread": "251.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "nSAEs and SAEs were collected from start of study treatment up to 16 weeks", "description": "nSAEs and SAEs were collected in Safety Population", "eventGroups": [{"id": "EG000", "title": "Part A: Placebo", "description": "Participants administered a single dose of placebo using ELLIPTA DPI via inhalation route.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 6, "otherNumAtRisk": 23}, {"id": "EG001", "title": "Part A: 50 \u00b5g OD", "description": "Participants administered a single dose of 50 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 9, "otherNumAtRisk": 12}, {"id": "EG002", "title": "Part A: 100 \u00b5g OD", "description": "Participants administered a single dose of 100 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 6, "otherNumAtRisk": 12}, {"id": "EG003", "title": "Part A: 200 \u00b5g OD", "description": "Participants administered a single dose of 200 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 7, "otherNumAtRisk": 13}, {"id": "EG004", "title": "Part A: 500 \u00b5g OD", "description": "Participants administered a single dose of 500 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 6, "otherNumAtRisk": 12}, {"id": "EG005", "title": "Part A: 1000 \u00b5g OD", "description": "Participants administered a single dose of 1000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 4, "otherNumAtRisk": 9}, {"id": "EG006", "title": "Part A: 2000 \u00b5g OD", "description": "Participants administered a single dose of 2000 \u00b5g GSK2292767 via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 5, "otherNumAtRisk": 12}, {"id": "EG007", "title": "Part B: Placebo", "description": "Participants were administered once daily dose of placebo for 14 days via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 3, "otherNumAtRisk": 3}, {"id": "EG008", "title": "Part B: 2000ug OD", "description": "Participants were administered 2000 \u00b5g GSK2292767 once daily for 14 days via inhalation route using ELLIPTA DPI", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 8, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Rhythm idioventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Gingival bleeding", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Lip ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Feeling cold", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Sunburn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Pain in jaw", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 9}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Suffocation feeling", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 4, "numAtRisk": 9}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Ear disorder", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Catheter site bruise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Catheter site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Vessel puncture site bruise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 9}]}, {"term": "Oropharyngeal candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Bronchoscopy abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 3, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 9}]}, {"term": "Sputum abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}, {"term": "Nasal obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 9}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "email": "GSKClinicalSupportHD@gsk.com", "phone": "866-435-7343"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-01-05", "uploadDate": "2018-04-26T07:44", "filename": "Prot_000.pdf", "size": 641737}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-05-23", "uploadDate": "2018-04-26T07:45", "filename": "SAP_001.pdf", "size": 478895}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}